Abstract Off-label use of medication is common in hospital clinical practice and should be applied together with follow-up of a healthcare treatment protocol and in compliance with a procedure which ensures that the patient is informed and that he or she provides informed consent.
Fuera de ficha técnica (FFT); Medicamentos en situaciones especiales
La revisión bibliográfica sobre manejo de 310 enfermedades puso de manifiesto que en 69 de ellas (22,3%) está descrito el uso de medicamentos en indicaciones off-label con un mínimo exigible de aval científico.
Introduction
Spanish Royal Decree 1015/2009, 1 which regulates the availability of medications in special situations, involves the following three components:
---Compassionate use of medications in research:
The use of a medication before it is authorised for commercial use in Spain in patients with chronic or severely debilitating diseases or life-threatening conditions that cannot be satisfactorily treated using authorised medications. The medication must be in the process of authorisation for commercialisation, or at least be subject to clinical trials.
---Use of medications under conditions other than those
authorised: The use of a medication under conditions other than those authorised in its summary of product characteristics (which is referred to in the scientific literature as ''off-label'' use).
---Access to medications that are not authorised in Spain:
The use of medications that are authorised in other countries, but not in Spain, when these do not fall within the definition of compassionate use of medication in research, as previously described.
With regard to access to medications in conditions different from those indicated in the summary of product characteristics, article 13.1 of the Royal Decree states that:
The use of authorised medications for uses other than those established in the summary of product characteristics will be exceptions to the rule, and this will be limited to those cases in which authorised therapeutic alternatives are not available to any given patient, while respecting any restrictions that may have been established with regard to the prescription and/or dispensing of the medication and the health care protocol at the hospital. The prescribing physician must explain the need for using the medication in the clinical history, and must inform the patient as to the possible benefits and potential risks of treatment, and obtain informed consent as per Law 41/2002 , of November 14.
Under these conditions, the use of a medication under circumstances other than those indicated in the summary of product characteristics has been established in common medical practice. Health care protocols also establish the possible alternatives for treatment and the order in which they may be used, and thus the attending physician must follow a protocol or series of restrictions for the prescription of these types of medications. Strict compliance is also needed with the law of patient autonomy with regard to obtaining informed consent.
2---4
We should consider that the approved indications in the summary of product characteristics established by the European Medicines Agency (EMEA) or the Spanish Agency for Medicines and Healthcare Products (AEMPS, for its initials in Spanish) do not necessarily coincide with those approved by other health agencies such as the Food and Drug Administration (FDA).
The off-label use of a medication can range from being the first option to being the last line of treatment. The conditions for the use of each medication must be well defined, since, if a drug is a more effective and/or safer therapeutic alternative than other, it may be the treatment of choice for the disease in question, regardless of the presence of its use for said condition on the summary of product characteristics.
Information is very scarce regarding the off-label use of medications. Some studies report that certain drugs are frequently used off-label. In the USA, the use of medications not approved by the FDA has been estimated at 21% of all prescriptions, although this percentage can be higher for certain drugs, such as gabapentin (83%), amitriptyline (81%), oral dexamethasone (79%), isosorbide mononitrate (75%), rituximab (75%), risperidone (66%) and digoxin (66%). According to the scientific literature, the same restrictions or level of evidence are not required for the off-label use of all medications, and although the off-label use of isosorbide mononitrate and digoxin is sufficiently accredited, the same cannot be said for gabapentin, risperidone, or amitriptyline. 5, 6 On the other hand, the off-label use of drugs can create conflicts for the different expectations held by certain interested parties: health administrators, physicians, the pharmaceutical industry, and patients. In this manner, 24, 25 health administrators may question the need for paying for unapproved drugs in the treatment of a disease, physicians may desire the freedom to prescribe whatever drugs they deem fit, the pharmaceutical industry may seek to expand the market with new drugs and new uses for established drugs, and finally, patients desire safe, effective, and accessible medications. 7 When evaluating the off-label inclusion of a drug in treatment protocols, several different important aspects must be taken into account 8, 9 :
---If the drug in question is new, the scientific evidence that endorses its off-label use may not be based on high-quality trials, and only limited information may be available regarding the safety of using the drug. ---If the drug in question has been commercialised for some time, its off-label use may involve widely ranging circumstances, varying from cases in which, due to a reduced price of the drug, the clinical costs for obtaining a new indication are not offset by the benefits acquired from a hypothetical authorisation of the new use, to those cases of a presumed lack of interest in obtaining authorisation for a new indication, such as in the use of bevacizumab in the treatment of age-related macular degeneration. The use of IV erythromycin in intestinal pseudo-obstruction is based on its activity as a motilin antagonist and gastric prokinetic agent. Dosage is 1 mg/kg every 8 h 40---42 Irritable bowel syndrome (IBS)
Tricyclic antidepressants Some studies support the use of tricyclic antidepressants in doses lower than those used to treat depression in order to improve visceral hypersensitivity (abdominal discomfort or pain at thresholds lower than those of healthy subjects) that occurs in patients with IBS. Other studies have produced inconsistent results
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---In the case of the off-label use of drugs with established severe adverse reactions, patient safety requires special attention. ---The off-label use of high-cost medications requires reasonable expectations with regard to clinical results. ---In all cases, the off-label use of medications requires some minimum level of scientific evidence that endorses said use.
Methods
With the objective of evaluating the off-label use of medications, we reviewed recent editions of two different Spanish manuals, the Cliniguía 13 (clinical guidelines) and Normas de actuación en urgencias 14 (emergency medicine guidelines).
They offer basic information regarding the management of different diseases in adults and are extensively used among physicians both in the primary care setting and specialised medicine. We also carried out a Medline literature search regarding the treatment of several different diseases, focusing on data compiled in clinical guidelines and recently published systematic reviews, and in their absence, publications that have been widely cited in medical literature. We considered those drugs whose use is recommended for the treatment of certain diseases in the cited sources and is not included in the summary of product characteristics detailed in the EMEA or AEMPS.
For the inclusion of a drug in this context, we evaluated the available evidence for its off-label use, according to the following criteria: The use of ketoconazole is based on the inhibition of cholesterol, sex steroid, and cortisol synthesis due to its activity on the enzymes 11␤-hydroxylase and C17-20-lyase. Ketoconazole is used in Cushing's syndrome at 400---1200 mg, divided into several administrations Mitotane diminishes cortisol production by blocking the cholesterol and 11␤-hydroxylase pathway Etomidate can be used to treat severely ill patients with ectopic ACTH production that cannot take oral treatment and require immediate correction of hypercortisolaemia. Administered by IV perfusion at 2.5 mg/h 53, 54 ---We did not include those drugs that the consulted medical texts mentioned as having a doubtful efficacy in the disorder in question. ---We did not include those drugs for which the consulted sources indicated the scarcity or deficiency of scientific literature endorsing their use for the disease in question. ---We did include drugs that have been recommended in all or most of the consulted sources. ---We did not consider off-label indications those diseases in which a proprietary drug did not include that particular indication but another drug exists (whether commercialised in Spain or not) with the same active ingredient for which the EMEA had approved said indication (for example, the indication for the treatment of sickle cell anaemia has not been approved for the brand name Hydrea ® , but this indication has been approved by the EMEA for another proprietary drug that also contains hydroxyurea, Siklos ® ). ---We also did not consider off-label use those cases in which the drug is employed using the conditions of administration and dosage established in the summary of product characteristics for certain approved indications which constitute a symptom or a sub-pathology of the primary disease (for example, the use of propranolol in porphyria 84 Altengurg et al., 85 Pizarro et al., 86 Rattan et al., 87 and Bonnetblanc et al. Cotrimoxazole is used to prevent relapse and acts through an unknown mechanism, although it is probably associated with anti-inflammatory or anti-oxidant activity, rather than due to its antibiotic activity 99 Rituximab has produced promising results in some studies, but further research is needed to confirm these findings 100 Systemic lupus erythematosus (SLE)
Rituximab Mycophenolate mofetil
Rituximab is used in severe resistant cases of SLE and lupus nephritis 101 Mycophenolate mofetil is used in lupus nephritis 102 Celecoxib: used as prophylaxis against heterotopic ossification due to surgical hip replacement Indomethacin: used as prophylaxis treatment against heterotopic ossification due to spinal injury or surgical hip replacement 103, 104 Behçet's syndrome Colchicine Infliximab Interferon alpha-2b Sulfasalazine Thalidomide
Colchicine: used to treat oral ulcers and cutaneous and joint manifestations Infliximab: used to treat uveitis and uveoretinitis Interferon alpha-2b: used to treat joint manifestations Sulfasalazine: used to treat intestinal manifestations Thalidomide: used to treat oral ulcers and gastrointestinal manifestations 105, 106 for the control of crises of tachycardia and hypertension, or drugs such as clozapine and quetiapine in Huntington's chorea for the treatment of associated psychosis). ---We did consider off-label use that, in the treatment of these sub-pathologies, the drug is administered at a dosage or form of administration different from that recommended in the summary of product characteristics (for example, omeprazole at high doses in continuous intravenous perfusion for upper gastrointestinal bleeding). ---We also considered off-label use that a drug is approved for any given indication by the FDA, but not by the EMEA or the AEMPS. ---For those drugs that had not been commercialised in Spain, we only considered off-label use to have occurred in those diseases that were not authorised as an indication in the summary of product characteristics from the country of origin.
Results
We reviewed manuals and protocols published on the management of 310 different diseases/treatment circumstances corresponding to the following medical spe In 69 of these diseases (22.3%), the off-label use of the drug was described.
The results detailed in our review are summarised in Tables 1---9. The column observations summarises the data that are especially relevant with regard to the off-label use 
Glucagon
The cardiac inotropic effects of glucagon are the basis of its use in the treatment of anaphylaxis in patients taking ␤-blockers, in which the response to adrenalin may be diminished, thus requiring a greater dose. In these patients, IV glucagon has been used at 5---10 mg in a single bolus followed by a perfusion at an initial rate of 4 mg/h, which is then progressively reduced 13 Amanita phalloides toxicity Penicillin G sodium Benzylpenicillin has been effectively used in dogs 5---24 h following poisoning by A. phalloides. The mechanism of action of penicillin against A. phalloides toxicity is unknown, and although it has been suggested that penicillin may inhibit the uptake of amatoxins by hepatocytes, this is still a point of controversy. Penicillin is administered at 300 000---1 000 000 UI/kg/day on continuous perfusion for treating A. phalloides toxicity. Treatment must be continued for several days, until all symptoms have disappeared. 107 Organophosphate toxicity Atropine Indication approved by the FDA. Administered along with pralidoxime 108, 109 Hypertensive emergencies Captopril Nifedipine
See Moya Mir et al. 115, 116 Unclogging venous catheters Urokinase Applied through an injection into the catheter 117 Kawasaki disease Acetylsalicylic acid (ASA) This indication is not included in the summary of product characteristics for ASA, but the concomitant use of immunoglobulin is mentioned in that for immunoglobulin IV ASA is indicated in Kawasaki disease at initial doses during the acute phase of 80---100 mg/kg/day (divided into 4 doses) for 14 days or up until 48---72 h after the patient's fever has ceased, and afterwards, at 3---5 mg/kg/day for 6---8 weeks or until platelet levels have normalised 118---120 of each drug. In addition to the bibliographic references, we mention the most relevant aspects of each use, i.e., the mechanism of action of the drug for the off-label indication, the line of treatment of the drug within the treatment plan, the approval of using the drug for a given pathology by the FDA (if the indication was not approved by the EMEA or the AEMPS), dosage (if the off-label indication is different from the approved uses), and any other aspect considered to be unusual in the off-label use of each drug.
Discussion
The off-label use of a drug can be based on any of the following circumstances:
---The assumption that a given drug will have a certain activity that is known to be present in other drugs of the same class (for example, the summary of product characteristics for buserelin and nafarelin do not mention indications for use in precocious puberty, which is an indication that has been approved for leuprorelin and triptorelin; the same goes for oral metronidazole as a adjuvant treatment in hepatic encephalopathy, which is an approved indication in other oral antibiotics that act on the intestines, such as paromomycin, neomycin, and rifaximin). ---An extension of the indications for a given drug to others that are 'related' to the already approved uses in the summary of product characteristics (for example, the off-label use of methotrexate in different auto-immune diseases, or the use of captopril or nifedipine in hypertensive emergencies, or adalumimab, which is approved for use in Crohn's disease and has an off-label use for ulcerative colitis). ---The use of a drug's mechanism of action in order to obtain a beneficial effect in an off-label indication (for example, using insulin to treat hypercalcaemia is based on the stimulation of potassium uptake in muscle, liver, and adipose cells; the use of ketoconazole in Cushing's syndrome is based on the inhibition of cholesterol, sex steroid, and cortisol synthesis due to its activity on the enzymes 11␤-hydroxylase and C17-20-lyase; the use of intravenous erythromycin in intestinal pseudo-obstruction is based on its action as a motilin antagonist and gastric prokinetic agent; the activity of metformin to improve peripheral uptake of insulin is the basis for its off-label use in polycystic ovary syndrome). ---In certain cases, the mechanism of action in the off-label indication is completely unknown (for example, the use of penicillin G to treat Amanita phalloides toxicity).
In the hospital environment, medications are frequently used off-label, and these situations should be compiled into health care protocols. The physician should comply with these protocols, and the Pharmacy and Therapeutics Committee should play an important role in their control.
A list of all diseases or treatment situations in which the scientific literature recommends the off-label use of drugs would also help the Pharmacy and Therapeutics Committee to provide reference information on the diseases for which drugs are frequently prescribed outside of the realm of their approved indications, and/or regarding those that should be used with special caution under a specific health care protocol.
Additionally, having a reference list for drugs used offlabel could help hospital pharmacists who must validate medical prescriptions in understanding and justifying certain prescriptions that at first glance might seem unreasonable (for example, prescribing ketoconazole in doses as high as 1200 mg/day to treat Cushing's syndrome and not a fungal infection; insulin can be used to treat hypercalcaemia even though the patient may not be diabetic; an intravenous dose of erythromycin as low as 1 mg/kg/8 h would indicate that the patient is being treated for intestinal pseudoobstruction; a prescription of 500 mg of azithromycin three times per week or 1200 mg once per week over 6 months would indicate that the patient has cystic fibrosis; the use of tamoxifen in a male patient would indicate that the patient does not have breast cancer, but rather a complication of peritoneal dialysis, such as sclerosing encapsulating peritonitis).
Furthermore, a list of off-label indications for medications would provide a significant help in incorporating a search index by disease, including a list of drugs used for each disease, in a hospital Pharmacotherapy Guide or any other database. This would provide incomplete information if only those indications approved by each medication's summary of product characteristics were to be included. 121 
